Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

Every year, a health care think tank called the Lown Institute ranks the 10 worst examples of "profiteering and dysfunction" ...